Suppr超能文献

[急性淋巴细胞白血病患儿预后及治疗失败的相关因素]

[Factors associated with prognosis and treatment failure in children with acute lymphoblastic leukemia].

作者信息

Yin Meng-Meng, Hu Qun, Liu Ai-Guo, Wang Ya-Qin, Zhang Ai

机构信息

Department of Pediatric Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.

出版信息

Zhongguo Dang Dai Er Ke Za Zhi. 2025 Mar 15;27(3):308-314. doi: 10.7499/j.issn.1008-8830.2409008.

Abstract

OBJECTIVES

To explore the factors related to prognosis and treatment failure in children with acute lymphoblastic leukemia (ALL).

METHODS

A retrospective study was conducted to collect and analyze clinical data of ALL children admitted to the Department of Pediatric Hematology at Tongji Hospital, Huazhong University of Science and Technology, from January 2012 to December 2019, with follow-up until June 2024.

RESULTS

A total of 341 children with ALL were included. Among the 69 children with treatment failure, 55 (80%) experienced relapse, while 14 (20%) had non-relapse-related deaths, and no secondary tumors were observed. Initial WBC count ≥50×10/L, positive minimal residual disease, and severe adverse events were identified as independent risk factors for treatment failure (<0.05). Among the 55 relapsed patients, early relapses were predominant (36%), and the primary site of relapse was the bone marrow (56%). Immunophenotyping (=0.009), initial WBC count (=0.011), and fusion genes (=0.040) were associated with the timing of relapse. High-risk status, T-cell ALL, relapse, and severe adverse events were independent risk factors affecting long-term survival (<0.05).

CONCLUSIONS

The prognosis of children with ALL is related to risk stratification, immunophenotyping, relapse status, and occurrence of severe adverse events. Among these factors, relapse is the primary cause of treatment failure. Actively preventing relapse may reduce the treatment failure rate and improve long-term survival.

摘要

目的

探讨急性淋巴细胞白血病(ALL)患儿预后及治疗失败的相关因素。

方法

进行一项回顾性研究,收集并分析2012年1月至2019年12月在华中科技大学同济医院小儿血液科住院的ALL患儿的临床资料,并随访至2024年6月。

结果

共纳入341例ALL患儿。在69例治疗失败的患儿中,55例(80%)复发,14例(20%)发生与复发无关的死亡,未观察到继发性肿瘤。初始白细胞计数≥50×10⁹/L、微小残留病阳性和严重不良事件被确定为治疗失败的独立危险因素(P<0.05)。在55例复发患者中,早期复发占主导(36%),复发的主要部位是骨髓(56%)。免疫表型分析(P=0.009)、初始白细胞计数(P=0.011)和融合基因(P=0.040)与复发时间相关。高危状态、T细胞ALL、复发和严重不良事件是影响长期生存的独立危险因素(P<0.05)。

结论

ALL患儿的预后与危险分层、免疫表型分析、复发状态和严重不良事件的发生有关。在这些因素中,复发是治疗失败的主要原因。积极预防复发可能降低治疗失败率并提高长期生存率。

相似文献

1
[Factors associated with prognosis and treatment failure in children with acute lymphoblastic leukemia].
Zhongguo Dang Dai Er Ke Za Zhi. 2025 Mar 15;27(3):308-314. doi: 10.7499/j.issn.1008-8830.2409008.
2
[The Factors Related to Treatment Failure in Children with Acute Lymphoblastic Leukemia].
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2021 Jun;29(3):661-668. doi: 10.19746/j.cnki.issn.1009-2137.2021.03.002.
3
[The Factors Related to Treatment Failure in Children with Acute Lymphoblastic leukemia--Analysis of Multi-Center Data from Real World in Fujian Province].
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2024 Dec;32(6):1656-1664. doi: 10.19746/j.cnki.issn.1009-2137.2024.06.005.
4
[Clinical features and long-term prognostic analysis of relapsed pediatric acute lymphoblastic leukemia].
Zhonghua Er Ke Za Zhi. 2024 Nov 2;62(11):1090-1096. doi: 10.3760/cma.j.cn112140-20240914-00643.
7
[Clinical Characteristics and Prognostic Analysis of Childhood Acute Lymphoblastic Leukemia with Positive Fusion Gene].
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2025 Apr;33(2):319-324. doi: 10.19746/j.cnki.issn.1009-2137.2025.02.002.
9
[The Factors Affecting Relapse in Pediatric B-cell Acute Lymphoblastic Leukemia Patients without Prognostic Fusion Genes Following Up for 10 years].
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2022 Feb;30(1):12-17. doi: 10.19746/j.cnki.issn.1009-2137.2022.01.003.
10
[Clinical Features and Prognosis of Acute T-cell Lymphoblastic Leukemia in Children--Multi-Center Data Analysis in Fujian].
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2024 Feb;32(1):6-13. doi: 10.19746/j.cnki.issn.1009-2137.2024.01.002.

本文引用的文献

1
[PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA].
Harefuah. 2023 Jan;162(1):57-63.
2
Antibiotic prophylaxis in acute childhood leukemia: What is known so far?
Hematol Transfus Cell Ther. 2023 Oct-Dec;45(4):473-482. doi: 10.1016/j.htct.2022.09.1279. Epub 2022 Nov 21.
4
Advances in the Diagnosis and Treatment of Pediatric Acute Lymphoblastic Leukemia.
J Clin Med. 2021 Apr 29;10(9):1926. doi: 10.3390/jcm10091926.
5
How we approach Philadelphia chromosome-positive acute lymphoblastic leukemia in children and young adults.
Pediatr Blood Cancer. 2020 Oct;67(10):e28543. doi: 10.1002/pbc.28543. Epub 2020 Aug 11.
6
How I treat relapsed acute lymphoblastic leukemia in the pediatric population.
Blood. 2020 Oct 15;136(16):1803-1812. doi: 10.1182/blood.2019004043.
7
Minimal Residual Disease Detection in Acute Lymphoblastic Leukemia.
Int J Mol Sci. 2020 Feb 5;21(3):1054. doi: 10.3390/ijms21031054.
9
Comparative features and outcomes between paediatric T-cell and B-cell acute lymphoblastic leukaemia.
Lancet Oncol. 2019 Mar;20(3):e142-e154. doi: 10.1016/S1470-2045(19)30031-2.
10
Treatment abandonment in childhood acute lymphoblastic leukaemia in China: a retrospective cohort study of the Chinese Children's Cancer Group.
Arch Dis Child. 2019 Jun;104(6):522-529. doi: 10.1136/archdischild-2018-316181. Epub 2019 Jan 31.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验